Search results
WE'RE RESEARCH-DRIVEN. Strong Presence in Singapore. At MSD, we are inspired by a shared vision and mission to save and improve lives.
We manufacture and package products that we distribute to more than 163 markets. MSD is committed to providing patients and customers with a reliable supply of high-quality, safe, and effective medicines and vaccines.
We manufacture and package products that we distribute to more than 163 markets. MSD is committed to providing patients and customers with a reliable supply of high-quality, safe, and effective medicines and vaccines.
If you have questions relating to MSD prescription products, your medical condition or personal health matters, please contact your physician or healthcare provider since he or she is most familiar with your medical condition.
MSD Manufacturing Division, located in Tuas, first began operations in 1997. Singapore has become a key strategic site in the MSD global manufacturing network, which consists of 43 manufacturing sites in 19 different countries, serving over 181 countries (as of Mar 2022).
MSD Singapore is more than just medicines, we invent for a more hopeful future. Our purpose: We use the power of leading-edge science to save and improve lives around the world For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.
MSD is a global health care leader working to help the world be well.
In Singapore, MSD has made investments in excess of USD$2 billion for manufacturing assets since 1997 and over USD$240 million in research since 2009. This demonstrates MSD’s commitment as a trusted supplier of pharmaceuticals, vaccines and biologics to the world’s patients and customers.
MSD began distributing a combined measles-mumps-rubella (M-M-R) vaccine that was developed by Drs. Maurice Hilleman and Eugene B. Buynak. M-M-R was composed of three vaccines: ATTENUVAX, an updated version of MSD’s measles vaccine; MERUVAX, a rubella vaccine; and MUMPSVAX, MSD’s mumps vaccine.
Oct 5, 2022 · SINGAPORE, October 5, 2022 – MSD (trade name of Merck & Co., Inc., Rahway, N.J., USA [NYSE: MRK]) announced the opening of a new secondary packaging facility to support the production of vaccines and biologics, including the company’s cancer immunotherapy products.
